Job Description Summary

Business Title: Operations Manager - Project Delivery & Manufacturing

#LI-Onsite

Location: Denton, TX

Join Novartis and help shape the future of radioligand therapy manufacturing from the ground up. As the Operations Manager - Project Delivery & Manufacturing, you will play a critical leadership role in supporting the ramp up of our new Radioligand Therapy manufacturing site in Denton, Texas. This unique opportunity places you at the intersection of project delivery, operational readiness, and manufacturing leadership, where you will build the foundation for a high-performing manufacturing organization while driving startup readiness, workforce development, cross-functional integration, and commercial launch success. As the site transitions into operations, you will lead Manufacturing Operations and help create a culture of safety, quality, operational excellence, and continuous improvement that supports patients around the world.

Job Description

Key Responsibilities

Lead operational readiness, startup planning, and commercialization activities for the Denton manufacturing site.
Support the ramp up of Novartis' new Radioligand Therapy manufacturing site in Denton, Texas.
Drive cross-functional project delivery, governance, and operational integration across site workstreams.
Build manufacturing capabilities through workforce planning, training, onboarding, and organizational development.
Lead Manufacturing Operations to achieve safety, quality, delivery, cost, and people objectives.
Develop high-performing teams while fostering accountability, operational excellence, and continuous improvement.
Establish systems, processes, and performance metrics that enable successful commercial manufacturing operations.

Essential Requirements

Bachelor's Degree in Engineering, Manufacturing, Operations, Supply Chain, Business, Military Science, or a related discipline.
6-10 years of progressive leadership experience in manufacturing, operations, engineering, logistics, supply chain, project management, military, or another complex operational environment.
Demonstrated experience leading cross-functional programs, operational initiatives, or large-scale projects.
Experience developing operational readiness programs, workforce strategies, training plans, or organizational buildout activities.
Proven ability to lead teams in dynamic environments while driving operational excellence and performance improvement.
Strong leadership, communication, planning, and organizational skills with the ability to influence across functions.

Desirable Requirements

Experience supporting startup, operational readiness, manufacturing operations, or organizational buildout activities.
Experience in pharmaceutical, biotechnology, Good Manufacturing Practice, or another regulated manufacturing environment.

The salary for this position is expected to range between $98,700 and $183,300 per year. The final salary offered is determined based on factors like, but not limited to, relevant skills and experience, and upon joining Novartis will be reviewed periodically. Novartis may change the published salary range based on company and market factors. Your compensation will include a performance-based cash incentive and, depending on the level of the role, eligibility to be considered for annual equity awards. US-based eligible employees will receive a comprehensive benefits package that includes health, life and disability benefits, a 401(k) with company contribution and match, and a variety of other benefits. In addition, employees are eligible for a generous time off package including vacation, personal days, holidays and other leaves.

To learn more about the culture, rewards and benefits we offer our people click here.

EEO Statement:

The Novartis Group of Companies are Equal Opportunity Employers. We do not discriminate in recruitment, hiring, training, promotion or other employment practices for reasons of race, color, religion, sex, national origin, age, sexual orientation, gender identity or expression, marital or veteran status, disability, or any other legally protected status.

Accessibility and reasonable accommodations

The Novartis Group of Companies are committed to working with and providing reasonable accommodation to individuals with disabilities. If, because of a medical condition or disability, you need a reasonable accommodation for any part of the application process, or to perform the essential functions of a position, please send an e-mail to [email protected] or call +1(877)395-2339 and let us know the nature of your request and your contact information. Please include the job requisition number in your message.

Salary Range

$108,500.00 - $201,500.00

Skills Desired

Data Analytics

About the company

Novartis is a global pharmaceutical company that uses science-based innovations to develop treatments and improve patient outcomes worldwide. Its products are medicines developed through research and development to address various diseases, aiming to reach nearly 1 billion people. The company differentiates itself by large-scale investment in R&D, a global presence with a diverse workforce, and a clear mission to Reimagine Medicine, focusing on meeting the changing needs of patients. Its goal is to improve quality of life and extend life expectancy by delivering meaningful therapies through its research and development efforts.

Company Size

10,001+

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1970

Get referred to Novartis

See people who can refer or advise you

Simplify's Take

What believers are saying

Ianalumab won FDA Breakthrough Therapy designation on January 16, 2026.
Remibrutinib posted positive Phase III data in April 2026 and September 2026.
The October 2, 2026 Abogen deal adds optionality across autoimmune RNA programs.

What critics are saying

Entresto generic erosion hits in November 2026 after a September 2026 patent-loss setback.
Reuters reported two late-stage failures in September 2026 erased nearly $30 billion.
Novartis faces India pricing pressure over ribociclib; Kerala High Court scrutiny continues.

What makes Novartis unique

Novartis pairs blockbuster execution with 2026 launches like Rhapsido and Itvisma.
Its 2026 autoimmune push spans remibrutinib, ianalumab, and Abogen's ABO2203.
CAS collaboration in September 2026 strengthens Novartis's AI-ready reaction data advantage.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options

Growth & Insights and Company News

6 month growth

-3%

1 year growth

-2%

2 year growth

-2%

Yahoo Finance

Oct 27th, 2026

Novartis raises 2026 profit guidance as Q3 sales rise 4% to $14.5B

Novartis raised its 2026 profit outlook after a strong third quarter. It now expects core operating income to be in line with last year or up by a low single-digit percentage, versus a previous forecast of a low single-digit decline. Net sales rose 4% in constant currency to $14.5 billion. Core operating income climbed 10% to $6 billion, and core earnings per share grew 8% to $2.46. Priority brands rose 29%, led by Kisqali (up 37%), Leqvio (up 63%), and Scemblix (up 67%). Reported operating income fell 61% to $1.8 billion, mainly because of a $1.9 billion partial impairment of Daldesiran after it missed its primary endpoint in a Phase III trial. Free cash flow was $5.1 billion for the quarter. Novartis has bought back $2.8 billion of shares under a program of up to $10 billion.

Incyte

Oct 24th, 2026

MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab | Incyte

Planegg/Munich, Germany, and Wilmington, Delaware, U.S., January 13, 2020 MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab - MorphoSys and Incyte to co-commercialize tafasitamab in the U.S. - Incyte has exclusive commercialization rights outside of the U.S.

Yahoo Finance

Oct 22nd, 2026

Novartis wins EU approval for Cosentyx in polymyalgia rheumatica, a first for IL-17A inhibitors

Novartis has won European Commission approval for Cosentyx to treat polymyalgia rheumatica in adults. It is the first IL-17A inhibitor cleared in Europe specifically for the condition. The approval rests on Phase III trial data supporting use in patients with limited treatment options. The new indication extends Cosentyx's reach in immunology, a priority area for the Swiss drugmaker, which has a market value of CHF241.2 billion. Analysts flag tighter pricing and reimbursement pressure in Europe as a risk for each added indication.

Asianet News

Oct 17th, 2026

Novartis discontinues mid-stage lupus trial in latest pipeline setback.

Novartis discontinues mid-stage lupus trial in latest pipeline setback. Published: Oct 17 2026, 04:05 AM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us The multi-location study aimed to evaluate the efficacy, safety, and tolerability of iptacopan (LNP023) in addition to standard-of-care treatment in lupus. * Iptacopan is sold under the brand name Fabhalta and is approved by the FDA for Paroxysmal Nocturnal Hemoglobinuria, Primary Immunoglobulin A Nephropathy, and C3 Glomerulopathy. * Novartis has faced multiple clinical setbacks over the past several weeks, including trial failures and development discontinuations. * According to data from Koyfin, 8 of the 23 analysts rate the stock a 'buy' or 'strong buy,' while 13 rate it a 'hold' and only two rate it 'sell.' Shares of Novartis (NVS) closed little changed on Friday after the company decided to discontinue its mid-stage trial of iptacopan in lupus nephritis. According to a federal clinical trials registry update, the company has concluded the study over 'strategic considerations.' It is unclear if the discontinuation was spurred by efficacy or safety concerns. The multi-location study aimed to evaluate the efficacy, safety, and tolerability of iptacopan (LNP023) in addition to standard-of-care treatment. The company decided to conclude the study after completing the first part, as per the database. Iptacopan is sold under the brand name Fabhalta and is approved by the FDA for Paroxysmal Nocturnal Hemoglobinuria, Primary Immunoglobulin A Nephropathy, and C3 Glomerulopathy. Latest pipeline setback for Novartis. Novartis has faced multiple clinical setbacks over the past several weeks. Last month, the company said that its late-stage trial of Pelacarsen, being developed as a treatment to lower elevated lipoprotein(a) or Lp(a) and reduce the risk of major cardiovascular events, missed its primary goal. The company also said that its late-stage trial of del-desiran in myotonic dystrophy type 1 (DM1) missed its primary endpoint. Besides the late-stage drug failures, the company also discontinued development of VHB937 in mid-September after a mid-stage study missed primary and secondary goals. Prior to that, in August, Novartis paused multiple autoimmune and neurology trials after three fatal cases of immune effector cell-associated hemophagocytic syndrome (IEC-HS) in patients taking its experimental therapy Rap-cel. According to data from Koyfin, 8 of the 23 analysts rate the stock a 'buy' or 'strong buy,' while 13 rate it a 'hold' and only two rate it 'sell.' How did NVS retail traders react? On Stocktwits, retail sentiment around NVS stock stayed within the 'bearish' territory over the past 24 hours, while message volume rose from 'low' to 'normal' levels. NVS stock has gained 9% year-to-date. For updates and corrections, email newsroom[at]stocktwits[dot]com. Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New

European Biotechnology

Oct 16th, 2026

Evotec fills CSO vacancy; Sibylla and AL-S Pharma name new CEOs.

Evotec fills CSO vacancy; Sibylla and AL-S Pharma name new CEOs. Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell European Biotechnology about the companies they join. This week: a swift scientific leadership change at Evotec, a broader reshuffle at Sibylla and a new CEO to guide AL-S Pharma toward Phase 3. Evotec: Joanna Holbrook takes over as CSO. Holbrook will join the management board on Nov. 1, succeeding Cord Dohrmann, who stepped down Sept. 30 by mutual agreement after 16 years in the role. Holbrook joins from Novo Nordisk, where she led research in cardiovascular, renal and hepatic disease as well as in vitro discovery platforms. At Evotec, she will oversee scientific strategy across its discovery and development services and technology platforms. Go deeper. Sibylla Biotech: Four executive changes ahead of the clinic. The Italian biotech named Usman Azam CEO and Gianluca Fuggetta CFO. Azam led CAR-T developer Tmunity Therapeutics for more than five years and previously headed Novartis' cell and gene therapies unit. Sibylla cofounder and former CEO Lidia Pieri becomes COO, while Elena Ardini moves up to CSO. The team will advance Sibylla's lead Cyclin D1 protein degrader toward a first human study. Go deeper. AL-S Pharma: Harry Welten becomes CEO. He succeeds Michael Salzmann as the Swiss biotech prepares a confirmatory Phase 3 trial of AP-101, an antibody targeting misfolded SOD1 in amyotrophic lateral sclerosis. Welten says financing and partnerships will be priorities. The company now aims to start Phase 3 in 2027, a shift from its March target of late 2026. Its earlier Phase 2 study met a primary endpoint focused on safety. Go deeper. Integra Therapeutics: Simon Dew joins to build partnerships. Dew becomes chief business officer at the Barcelona biotech, joining from Macomics after earlier business development roles at several cell and gene therapy companies. Integra wants him to find partners for FiCAT, its preclinical gene-writing platform for cell and gene therapies. The company closed a €10.7 million financing in 2025, intended to validate CAR-T applications and prepare the technology for transfer to pharma partners. Go deeper. TETRAPHARM: Rolf Sass Sørensen succeeds a cofounder. Sørensen became CEO on Oct. 6, replacing Martin Rose. Rose and fellow cofounder Jesper Breum are leaving operational roles to pursue new biotech ventures but remain shareholders. Sørensen, a former Bavarian Nordic investor relations executive, takes over a business combining preclinical drug programs with contract development and manufacturing services. Go deeper. | (C) european biotechnology | Joachim Eeckhout 16 October 2026 |

Novartis

Operations Manager - Project Delivery & Manufacturing - Project Delivery & Manufacturing

About the job